Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

Developing tailored therapeutic strategies for brain arteriovenous malformations

EF 2025-26

Résumé
Brain arteriovenous malformations (bAVMs) are tangles of abnormal blood vessels that can rupture, leading to serious disability or death. Current treatment options-including surgery, endovascular intervention, and radiosurgery-carry inherent risks and potential for disease recurrence, highlighting a pressing need for less invasive alternatives such as oral therapies. Recent studies have identified a common, non-inherited mutation in the KRAS-MEK-ERK signaling pathway, which plays a central role in normal vascular development. This pathway is also well-established in cancer biology, and several drugs that target this pathway are already used for systemic tumor treatment (e.g., trametinib). Preclinical models of bAVMs demonstrate that trametinib can inhibit early bAVM formation, and clinical trials are now underway to evaluate its efficacy in patients. The exploration of drug therapies for bAVMs, however, raises concerns regarding systemic toxicity and potential drug resistance. In oncology, combining therapeutic agents is a well-established strategy to reduce required doses, overcome resistance, and minimize adverse effects. Analogously, our research seeks to identify effective drug combinations for bAVMs and to explore the potential of adjunctive therapies, such as radiation, to further reduce systemic toxicity. Through this work, we aim to advance the understanding of bAVM biology and elucidate how these lesions respond to pharmacologic intervention. Clinically, our goal is to contribute to the development of safer, less invasive treatment options for patients with bAVMs.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559633
Name
Jung Youngkyung
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Developing tailored therapeutic strategies for brain arteriovenous malformations
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Brain Arteriovenous Malformation; Brain Arteriovenous Malformations; Combinatorial Therapy; Drug Delivery; Genotype-Driven Therapy; Molecular And Cell Biology
Abstract
Brain arteriovenous malformations (bAVMs) are tangles of abnormal blood vessels that can rupture, leading to serious disability or death. Current treatment options-including surgery, endovascular intervention, and radiosurgery-carry inherent risks and potential for disease recurrence, highlighting a pressing need for less invasive alternatives such as oral therapies. Recent studies have identified a common, non-inherited mutation in the KRAS-MEK-ERK signaling pathway, which plays a central role in normal vascular development. This pathway is also well-established in cancer biology, and several drugs that target this pathway are already used for systemic tumor treatment (e.g., trametinib). Preclinical models of bAVMs demonstrate that trametinib can inhibit early bAVM formation, and clinical trials are now underway to evaluate its efficacy in patients. The exploration of drug therapies for bAVMs, however, raises concerns regarding systemic toxicity and potential drug resistance. In oncology, combining therapeutic agents is a well-established strategy to reduce required doses, overcome resistance, and minimize adverse effects. Analogously, our research seeks to identify effective drug combinations for bAVMs and to explore the potential of adjunctive therapies, such as radiation, to further reduce systemic toxicity. Through this work, we aim to advance the understanding of bAVM biology and elucidate how these lesions respond to pharmacologic intervention. Clinically, our goal is to contribute to the development of safer, less invasive treatment options for patients with bAVMs.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jung, Youngkyung
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~